Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

Ontario Institute for Cancer Research (Toronto, Ontario)

$1,201,050.00

Discovery and functional validation of non-coding cancer driver mutations for biological insights and target discovery

FY 2024-25

Summary
Cancer is a genetic disease. However, it is usually not inherited but is instead caused by mutations in DNA that accumulate in cells over time. Each cancer is caused by a few "driver" mutations that unlock cancerous properties of cells, such as endless growth or inability to die. Cancers also have thousands of "passenger" mutations that do not contribute to the disease. Thus, finding driver mutations is like finding needles in a haystack. Hundreds of drivers have been found until now, however most efforts have focused on a few percent of the genome that encodes proteins, the building blocks of cells. The remaining "non-coding" genome is much less understood; however, we know that it controls how genes are activated. While we only know little of non-coding genome, researchers are now finding non-coding mutations that contribute to cancer. With new large whole-genome datasets of cancer, we can better find and describe these mutations. In this project, we will combine advanced computational analysis and wet-lab experiments to find non-coding driver mutations in several major types of cancer. First, we use computer algorithms to sift through a hundred million mutations to find novel drivers. Second, we will build a rich profile for each new driver we find, describing the potential ways it contributes to cancer and whether its presence helps identify high-risk patients. Third, we will study the most prominent drivers with molecular experiments in cancer cells and mouse models. This will allow us to understand precisely how the drivers start cancer or make it more aggressive. Once we figure out how these novel drivers contribute to cancer, we may be able to block their activity to develop new cancer therapies in the future.
Program
Project Grant
Location
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
508691
Name
Reimand Jüri
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Discovery and functional validation of non-coding cancer driver mutations for biological insights and target discovery
Programtype2
Operating Grants
Orgnameinp2
Ontario Institute for Cancer Research (Toronto, Ontario)
Cihramount2
$1,201,050
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Biomarkers; Cancer Genomics; Crispr Screens; Driver Mutations; Genome Editing; Machine Learning; Non-Coding Genome; Oncogenes; Preclinical Study; Tumor Suppressors
Abstract
Cancer is a genetic disease. However, it is usually not inherited but is instead caused by mutations in DNA that accumulate in cells over time. Each cancer is caused by a few "driver" mutations that unlock cancerous properties of cells, such as endless growth or inability to die. Cancers also have thousands of "passenger" mutations that do not contribute to the disease. Thus, finding driver mutations is like finding needles in a haystack. Hundreds of drivers have been found until now, however most efforts have focused on a few percent of the genome that encodes proteins, the building blocks of cells. The remaining "non-coding" genome is much less understood; however, we know that it controls how genes are activated. While we only know little of non-coding genome, researchers are now finding non-coding mutations that contribute to cancer. With new large whole-genome datasets of cancer, we can better find and describe these mutations. In this project, we will combine advanced computational analysis and wet-lab experiments to find non-coding driver mutations in several major types of cancer. First, we use computer algorithms to sift through a hundred million mutations to find novel drivers. Second, we will build a rich profile for each new driver we find, describing the potential ways it contributes to cancer and whether its presence helps identify high-risk patients. Third, we will study the most prominent drivers with molecular experiments in cancer cells and mouse models. This will allow us to understand precisely how the drivers start cancer or make it more aggressive. Once we figure out how these novel drivers contribute to cancer, we may be able to block their activity to develop new cancer therapies in the future.
Competitiondate
202409
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Reimand, Jüri
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,201,050~ $0~
Ontario Institute for Cancer Research (Toronto, Ontar… | Canada Spends